The present study aimed to determine the bioaccessibility
and bioavailability
of peptide fractions with angiotensin-converting enzyme inhibition
(ACEI) from fermented milk with Lactococcus lactis NRRL B-50571 (FM-571) after being subjected to simulated gastrointestinal
digestion (SGD) and an ex vivo absorption model. Results showed that
ACEI increased (p < 0.05) after SGD and decreased
(p < 0.05) after absorption. Conversely, the IC50 decreased (p < 0.05) after SGD and after
absorption. Moreover, peptide abundance increased (p < 0.05) after SGD, indicating augmented bioaccessibility. Thereafter,
peptide abundance decreased (p < 0.05) after absorption,
resulting in 1.36 ± 0.1% of peptide bioavailability. Furthermore,
RP-HPLC collected fractions from the serosal compartment exhibited
the lowest IC50. 113 peptides were identified in the serosal
compartment, from which 14 bioavailable peptides showed high binding
potential to ACE after in silico analysis. Henceforth, these results
suggest that novel peptides derived from FM-571 with ACEI were bioavailable.